

In 2024, PYC therapeutics started two ADOA studies, the SUNDEW and the BANSKIA studies. SUNDEW is a safety-trial based in Australia, where patients actually get the experimental ADOA-medication called PYC-001, while BANSKIA is a natural history study with sites in Australia, US, UK, Netherlands, Germany, Austria, where patients are tested to see how ADOA progresses without any medication

Due to unforeseen regulatory challenges in Europe, PYC Therapeutics has decided to terminate the BANKSIA study. Instead, the company is focusing on interventional trials (trials with medication) with PYC-001, primarily the ongoing SUNDEW study in Australia. For this study, 5 additional patients from Australia are required, to be able to give reliable results for the safety of PYC-001.

In addition, studies involving multiple repeat doses of PYC -001 is expected to begin enrolling patients in late 2025 across Australia, the US, the UK, and in several sites across the EU. However, the specific sites for the multi-dose study are still being finalized. Patients interested in future trials can already register via PYC's SUNDEW mailbox here, and please state clearly if you are an Australian patient registering for SUNDEW, or for the multidose study (open to participants in multiple countries): sundew@pyctx.com

The Cure ADOA foundation and PYC are working together to ensure clear patient communication regarding these changes.